The BioHub - by Avetix

Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. We have Barbara Ryan who has over 40 years in Healthcare capital Markets with 31 years on wall street! She currently serves on 6 biotech boards including Indivior and MINK. She has raised over $1.5B for emerging biopharma companies in IPOs, follow-ons and convertible debt transactions. She is also the Founder of Fabulous Pharma Females, a non-profit dedicated to advancing and mentoring women in biopharma. Enjoy and stay tuned.

Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. We have Owen Hughes who has spent the last 25 years in healthcare as both an operator and investor. Currently the CEO of XOMA, former CEO of Sail Bio and former CEO and co-founder of Cullinan Oncology, who did $380M in private raises before a $250M IPO in 2021. Prior to Cullinan he served as CBO for Intarcia Therapeutics. He started his career on wall street, initially in equity research at Morgan Stanley before transitioning to buyside, where he managed public and private healthcare investments for Brookside Capital. Hewas also the Chairman of Radius Health before it’s sale of 890 million dollars, Lead independent director for Translate bio before it’s sale of $3.2B and is currently Chairman of Ikena Oncology. Enjoy and stay tuned.

Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. This week we welcome Frank Watanabe! CEO and President of Arcutis Therapeutics, where he has been since it's founding in 2016. During that time they have done multiple successful raises, an $160M IPO and have developed more than 2 FDA approved products with a 3rd being reviewed. Before this he was COO and co-founder of Kanan Therapeutics and VP of strategy and corporate development at Kythera. He also held numerous exec roles throughout his time at Amgen and Eli Lilly and was involved in the development and marketing of 3 approved drugs. He was also a commissioned officer in the US Navy reserves for 25 years. Enjoy and stay tuned.

Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. This week we welcome Paul Peter Tak! CEO and President of Candel Therapeutics From a professorship in his native Netherlands to the SVP, Chief Immunology Officer, and global development leader at GSK, and from leading small biotechs such as Tempero and Kintai to entering the venture world as a Flagship partner.   Now, he is the CEO and President of Candel Therapeutics – a promising clinical immunotherapy company in the fight against cancer. Enjoy and stay tuned.

Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. 40 years of experience across biotech and pharma! 6 years as CEO of Ipsen, where he currently serves as Chairman. He led the successful sale of Cincor Pharma for 1.8 Billion dollars to Astrazeneca and the sale of Corvidia to Novo Nordisk for 2.1 billion dollars. Now he serves as the CEO of Abivax, who just completed the largest ever NASDAQ IPO for a French biotech! Enjoy and stay tuned

Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. This week we welcome Dr Stanley Lewis the CEO and founder of A28 Therapeutics. With a remarkable 25-year career in life sciences across clinical research, and drug development, he is a true leader in the field. Formerly Chief Medical Officer at Ansun Biopharma, he successfully led late-stage trials, helped secure a $100 million Series B, and contributed to strategic in-licensing efforts. In 2021, he founded A28, aiming to revolutionize global cancer care. Enjoy and stay tuned

Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. This week we welcome Dr. Chris Mirabelli, who has 40 years of experience across Biotech and Pharma. Currently serving as Chairman of Leap Therapeutics, where he was the CEO from its founding in 2015 until 2020. A managing Director of HealthCare ventures, where since joining in 2000, they have raised 1 billion dollars across 4 funds and has been involved in over 15 investments leading to successful exits. Before his VC ventures, he was the CEO and Chairman of LeukoSite from its inception in 1993 until its acquisition by Millennium in 1999. Before that he was a co-founder of Ionis Pharma who today sit at a 7-billion-dollar market cap and a workforce of 1,000 employees. Enjoy and stay tuned

Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. This week we welcome Dr. Michael Tusche, who has 20 years of experience spanning, science, wall street and biotech. He was employee number one and co-CEO of Treadwell Therapeutics where they raised $118M, advanced 3 assets into the clinic and expanded the team to 50+. Enjoy and stay tuned.

We recently spoke to Lance Baldo, CEO of Beacon Therapeutics, during the Jefferies Healthcare Conference. Beacon's Vista ph3 trial for laru-zova, their AAV Gene Therapy for X-Linked Retinitis Pigmentosa, has completed enrolment with topline expected in mid-2026.Listen in to hear about Lance's career, from roles with Roche in both Switzerland & New Zealand to a return to the US with Genentech's ophthalmology division, and how he's drawn on those experiences in his role as CEO of Beacon.We also cover Lance's experience as a first-time CEO, and his advice for other executives making that transition, on topics as broad as fundraising, regulatory discussions, and team building. And of course, we cover the story behind Beacon & their mission to deliver a step-change for XLRP patients globally.